Additionally, the positive rate of Toxo-IgM antibodies was the highest in intracranial tumors (7.69%), followed by lymphoma (4.76%), and the lowest in nasopharyngeal carcinoma (1.45%). This evidence concerns the gene CD40LG and nasopharyngeal carcinoma.